Novo Nordisk A/S announced that its Annual General Meeting will take place on March 27, 2025, with key agenda items including Board member re-elections and a proposed dividend increase of 21% to DKK 11.40 per share, reflecting strong company performance. Additionally, the company plans a DKK 59 billion investment in expanding production facilities for chronic disease treatments.